Inhibiting tryptase after ischemia limits small intestinal ischemia-reperfusion injury through protease-activated receptor 2 in rats

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 5, 2012, Pages 1138-1144

  Liu, Dezhao ^a   Gan, Xiaoliang ^a   Huang, Pinjie ^a   Chen, Xinzhi ^a   Ge, Mian ^a   Hei, Ziqing ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Intestinal injury; Intestinal ischemia reperfusion; Mast cell tryptase; PAR 2; Rats

Indexed keywords

INTERLEUKIN 8; PROTAMINE; PROTEINASE ACTIVATED RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; INTESTINAL ISCHEMIA REPERFUSION INJURY; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SHAM PROCEDURE;

ANIMALS; CROMOLYN SODIUM; INTESTINE, SMALL; ISCHEMIA; MALE; MAST CELLS; P-METHOXY-N-METHYLPHENETHYLAMINE; PROTAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; REPERFUSION INJURY; TRYPTASES;

EID: 84869866844     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318265d08d     Document Type: Article

References (34)

1. Pierro A, Eaton S. Intestinal ischemia reperfusion injury and multisystem organ failure. Semin Pediatr Surg. 2004;13: 11-17.
2. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil. 2006;18: 6-17.
3. Rattmann YD, Pereira CR, Cury Y, Gremski W, Marques MC, da Silva- Santos JE. Vascular permeability and vasodilation induced by the Loxosceles intermedia venom in rats: involvement of mast cell degranulation, histamine and 5-HT receptors. Toxicon. 2008;51: 363-372.
4. Boros M. Microcirculatory dysfunction during intestinal ischemiareperfusion. Acta Physiol Hung. 2003;90: 263-279.
5. Hei ZQ, Gan XL, Huang HQ, Luo GJ, Li SR, Cai J. Protective effects of cromolyn sodium on intestinal ischaemia-reperfusionYtriggered lung injury in rats. Br J Anaesth. 2007;98: 407-408.
6. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempurai D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25: 563-568.
7. Hallgren J, Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006;273: 1871-1895.
8. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev. 2007;217: 141-154.
9. Kunder CA, St John AL, Abraham SN. Mast cell modulation of the vascular and lymphatic endothelium. Blood. 2011;118: 5383-5393.
10. Jacob C, Yang PC, Darmoul D, Amadesi S, Saito T, Cottrell GS, Coelho AM, Singh P, Grady EF, Perdue M, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem. 2005;280: 31936-31948.
11. Mullan CS, Riley M, Clarke D, Talter A, Sutcliffe A, Knox AJ, Pang L. Beta-tryptase regulates IL-8 expression in airway smooth muscle cells by a PAR-2Yindependent mechanism. Am J Respir Cell Mol Biol. 2008; 38: 600-608.
12. Kalia N, Brown NJ, Wood RF, Pockley AG. Ketotifen abrogates local and systemic consequences of rat intestinal ischemia-reperfusion injury. J Gastroenterol Hepatol. 2005;20: 1032-1038.
13. Szabó A, Boros M, Kaszaki J, Nagy S. The role of mast cells in mucosal permeability changes during ischemia-reperfusion injury of the small intestine. Shock. 1997;8: 284-291.
14. Hei ZQ, Gan XL, Huang PJ,Wei J, Shen N, Gao WL. Influence of Ketotifen, Cromolyn Sodium, and Compound 48/80 on the survival rates after intestinal ischemia reperfusion injury in rats. BMC Gastroenterol. 2008;8:42.
15. Oltean M, Olausson M. The Chiu/Park scale for grading intestinal ischemia-reperfusion: if it ain't broke don't fix it. Intensive Care Med. 2010;36:1095.
16. Thakurdas SM, Melicoff E, Sanscores-Garcia L, Moreira DC, Petrova Y, Stevens RL, Adachi R. The mast cell-restricted tryptase mMcp-6 has a critical immunoprotective role in bacterial infections. J Biol Chem. 2007; 282: 20809-20815.
17. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Timecourse analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106: 1864-1866.
18. Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine M, Williams H, Ramma W, Sissaoui S, Jayaraman PS, Ohba M, et al. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension. 2010;55: 689-697.
19. Hei ZQ, Huang PJ, Gan XL, Pang HY, Wei J. Influence of cromolyn sodium and compound 48/80 administered prior to and after reperfusion on the third day's survival rate in a rat intestinal ischemia model. Chin Med J (Engl). 2008;121: 1843-1847.
20. Dahai BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res. 2011;21:60.
21. Schewartz LB, Bradford TR. Regulation of tryptase from human lung mast cell by heparin. Stabilization of the active tetramer. J Biol Chem. 1986:261: 7372-7379.
22. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6: 135-142.
23. Andoh A, Fujiyama Y, Araki Y, Kimura T, Tsujikawa T, Bamba T. Role of complement activation and mast cell degranulation pathogenesis of rapid intestinal ischemia/reperfusion injury in rats. Digestion. 2001;63(Suppl 1): 103-107.
24. Hamilton MJ, Sinnamon MJ, Lyng GD, Glickman JN, Wang X, Xing W, Krilis SA, Blumberg RS, Adachi R, Lee DM, et al. Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci U S A. 2011; 108: 290-295.
25. The FO, Bennink RJ, Ankum WM, Buist MR, Busch OR, Gouma DJ, van der Heide S, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut. 2008;57: 33-40.
26. Pejler G. Mast cell chymase in complex with heparin proteoglycan is regulated by protamine. FEBS Lett. 1996;383: 170-174.
27. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry. 2001;40: 7342-7349.
28. Pope MR, Hoffman SM, Tomlinson S, Fleming SD. Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol. 2010;48: 356-364.
29. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci. 2004;49: 1359-1377.
30. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. Interdicting protease-activated receptor-2Ydriven inflammation with cellpenetrating pepducins. Proc Natl Acad Sci U S A. 2011;108: 8491-8496.
31. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia- Villar R, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161: 1903-1915.
32. Shea-Donohue T, Notari L, Stiltz J, Sun R, Madden KB, Urban JF Jr, Zhao A. Role of enteric nerves in immune-mediated changes in proteaseactivated receptor 2 effects on gut function. Neurogastroenterol Motil. 2010;22:1138Ye291.
33. Carvalho RF, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp Dermatol. 2010;19: 117-122.
34. Jennewein C, Paulus P, Zacharowski K. Linking inflammation and coagulation: novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol. 2011;24: 375-380